Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07284927 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.
Trial Details
NCT Number NCT07284927
Lead Sponsor PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Conditions Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov